Abstract
WEE1 Inhibitor AZD1775 as a Promising Therapeutic Approach for Ovarian Cancer
Highlights
Epithelial ovarian cancer is the most deadly of the gynecologic malignancies
Cancer cells with wild-type p53 activate G1/S checkpoint by inducing p21 Cdkn1a /Cip1/ Waf1.Cancer cells withTP53LOF mutations or p53-null are sensitive to tyrosine kinase inhibitors gefitinib or BIBF1120 combination with paclitaxel [6,7]
The PARP inhibitor olaparib has been approved as a mono therapy for recurrent ovarian cancer patients with BRCA1/2 mutations who have had three prior chemotherapy treatments [8]
Summary
Epithelial ovarian cancer is the most deadly of the gynecologic malignancies. The asymptomatic nature of the disease and a high rate of chemo resistance result in a long-term survival rate of only 30%. Cancer cells with wild-type p53 activate G1/S checkpoint by inducing p21 Cdkn1a /Cip1/ Waf1.Cancer cells withTP53LOF mutations or p53-null are sensitive to tyrosine kinase inhibitors gefitinib or BIBF1120 combination with paclitaxel [6,7]. BRCA1 and BRCA2 mutations are actionable genetic mutations in ovarian cancer. The PARP inhibitor olaparib has been approved as a mono therapy for recurrent ovarian cancer patients with BRCA1/2 mutations who have had three prior chemotherapy treatments [8].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Cell Science & Molecular Biology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
